We further investigated the potential value of combined inhibition of MET and VEGF signaling to block the positive feedback loop in improving gefitinib sensitivity in drug-resistant NSCLC cells with EGFR mutation and abnormal MET activation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.